Avecho is a speculative but highly asymmetric biotech option: a Sandoz-backed, patent-protected CBD insomnia readout could transform a low-revenue manufacturer into a high-margin royalty company—or clinical failure could erase most of the investment case.
Overview
Avecho Biotechnology is a Melbourne-based clinical-stage biotech centered on TPM®, a patented Vitamin E-derived delivery technology that improves solubility, stability, and absorption of difficult-to-deliver molecules. Existing revenue comes from Vital ET® manufacturing for Ashland and topical diclofenac licensing, but the main value driver is its Phase III oral CBD soft-gel for chronic insomnia. The asset is partnered with Sandoz for Australian commercialization, with milestones and tiered royalties. Superior CBD bioavailability, large sleep-market demand, and a potential first OTC Schedule 3 approval create substantial upside, offset by binary clinical and regulatory risk.